Transaction Overview - The acquisition of Eastern Michigan Financial Corporation (EFIN) by Mercantile Bank Corporation (MBWM) is valued at approximately $95.8 million[22] - The consideration mix is approximately 52% stock and 48% cash[22] - Cost savings are expected to be approximately $5.4 million pre-tax, representing ~40% of EFIN's noninterest expense[22] Financial Highlights of EFIN - EFIN has total assets of $505 million[12] - Gross loans amount to $208 million[12] - Total deposits are $449 million[12] - EFIN's loans-to-deposits ratio is 46%[12] - The cost of deposits is 0.42%[12] - Core deposits represent 99% of total deposits[12] Strategic Rationale - Eastern's superior deposit franchise, ranked 1 in Michigan, addresses Mercantile's key strategic priorities[9, 10] - The acquisition provides market expansion into Eastern Michigan[9] - The transaction is expected to result in strong double-digit earnings accretion[9]

Core Viewpoint - First Community Bankshares, Inc. is set to acquire Hometown Bancshares, Inc. in a strategic merger aimed at expanding its presence in West Virginia and enhancing its service offerings [1][2][4]. Company Overview - First Community Bankshares, Inc. is headquartered in Bluefield, Virginia, and operates through its subsidiary, First Community Bank, which has 52 branch locations across Virginia, West Virginia, North Carolina, and Tennessee. As of March 31, 2025, it reported consolidated assets of $3.2 billion [7]. - Hometown Bancshares, Inc. is based in Middlebourne, West Virginia, and offers banking services through its subsidiary, Union Bank, which operates eight locations and had total assets of approximately $402 million as of June 30, 2025 [9]. Merger Details - The merger agreement stipulates that Hometown will merge into First Community, with First Community as the surviving entity. Each share of Hometown common stock will convert into 11.706 shares of First Community common stock, valuing the transaction at approximately $41.5 million based on a share price of $40.33 as of July 18, 2025 [4][5]. - Upon completion, First Community is expected to have total consolidated assets of approximately $3.6 billion and operate 60 branch locations across four states [1][4]. Strategic Rationale - The merger aligns with First Community's strategy to grow low-cost core deposits and expand its market presence in the Parkersburg-Marietta-Vienna MSA. The partnership is seen as a natural extension into West Virginia markets similar to those where First Community has previously succeeded [2][3]. - First Community aims to enhance its service offerings by providing Trust and Wealth Management services, which are currently not available through Union Bank [3]. Financial Implications - The transaction is expected to be minimally dilutive to tangible book value per share and to provide high-single digit accretion to earnings per share [4]. - The merger has received unanimous approval from both companies' Boards of Directors and is subject to customary closing conditions, including shareholder approval and regulatory approvals, with an expected completion in the first quarter of 2026 [5].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating Olo Inc. and its leadership for potential breaches of fiduciary duties related to the company's pending acquisition by Thoma Bravo at a price of $10.25 per share [1][4]. Group 1: Company Overview - Olo Inc. operates as an open SaaS platform for restaurants, facilitating digital commerce operations including ordering, delivery, engagement, and payments [3]. - The company's stock is divided into Class A and Class B shares, with Class B shares having ten votes per share compared to one vote for Class A shares [3]. - As of December 31, 2024, directors and executive officers collectively owned approximately 82% of the voting power of Olo's outstanding capital stock [3]. Group 2: Acquisition Details - On July 3, 2025, Olo announced a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valued at approximately $2 billion in equity [3]. - Shareholders will receive $10.25 per share, representing a 65% premium over Olo's unaffected share price of $6.20 as of April 30, 2025 [3]. Group 3: Legal Investigation - The investigation by BFA Law focuses on whether Olo's board, executive officers, and CEO Noah H. Glass breached their fiduciary duties in connection with the merger [4]. - Current shareholders of Olo are encouraged to seek additional information regarding their legal options [2][5].

Group 1 - Omnicom's acquisition of Interpublic has received approval from the Australia Competition and Consumer Commission (ACCC), marking the 14th out of 18 necessary antitrust approvals for the transaction [1] - The merger is expected to transform the marketing industry, leading to growth for employees, improved client outcomes, and significant long-term value for shareholders [2] - Omnicom is a leading provider of data-inspired marketing solutions, serving over 5,000 clients in more than 70 countries [3] Group 2 - Interpublic is a creatively driven marketing solutions provider, home to many well-known global brands and communications specialists [4]

Core Viewpoint - Aptorum Group Limited has announced a definitive agreement for an all-stock merger with DiamiR Biosciences, which will become a wholly-owned subsidiary of Aptorum, retaining its name and continuing to be listed on the Nasdaq Stock Market after the merger [1][4]. Company Overview - Aptorum Group is a clinical stage biopharmaceutical company focused on addressing unmet medical needs in oncology and infectious diseases [8]. - DiamiR Biosciences specializes in developing proprietary blood-based tests for brain health and other diseases, operating a CLIA licensed, CAP accredited clinical laboratory [1][9]. Merger Details - The merger will involve Aptorum re-domiciling to Delaware and acquiring all outstanding capital stock of DiamiR in exchange for shares representing approximately 70% of the combined company's common stock, with current Aptorum equity holders retaining 30% [3][4]. - The merger agreement has been approved by the boards of both companies and is subject to stockholder approval and customary closing conditions, with an expected closing in the fourth quarter of 2025 [4][6]. Leadership and Structure - Post-merger, the combined company will be headquartered in Princeton, New Jersey, with Ian Huen as CEO, Dr. Alidad Mireskandari as President and COO, and Gary Anthony as CFO [5]. - The board of directors will consist of five members, with three designated by Aptorum and two by DiamiR [5]. Strategic Goals - The merger aims to create a global life sciences company capable of generating revenue through biopharma services and offering biomarker panels for complex-biology indications, particularly in aging-related diseases and brain health [2][3]. - DiamiR's expertise in assay development and commercialization is expected to enhance the combined company's capabilities in non-invasive blood-based testing [2].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating Olo Inc. and its leadership for potential breaches of fiduciary duties related to the company's pending acquisition by Thoma Bravo for $10.25 per share, valuing Olo at approximately $2 billion in equity [1][3][4]. Company Overview - Olo Inc. operates an open SaaS platform for restaurants, facilitating digital commerce operations including ordering, delivery, engagement, and payments [3]. - The company's stock is divided into Class A and Class B shares, with Class B shares having ten votes per share compared to one vote for Class A shares. As of December 31, 2024, directors and executive officers collectively owned approximately 82% of the voting power of Olo's outstanding capital stock [3]. Acquisition Details - On July 3, 2025, Olo announced a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction [3]. - The acquisition price of $10.25 per share represents a 65% premium over Olo's unaffected share price of $6.20 as of April 30, 2025, indicating a significant increase in shareholder value [3].

Core Viewpoint - DallasNews Corporation is set to be acquired by Hearst, enhancing its legacy of independent journalism with Hearst's resources and industry reputation [1][3]. Company Overview - DallasNews Corporation is the holding company for The Dallas Morning News and Medium Giant, known for its strong journalistic reputation and community ties [7]. - The Dallas Morning News has won nine Pulitzer Prizes, highlighting its commitment to quality journalism [7]. - Medium Giant is an integrated creative marketing agency that has received multiple industry awards, including the AAF Addy and the AMA DFW Annual Marketer of the Year [8]. Acquisition Details - Shareholders of DallasNews will receive $14.00 in cash per share, representing a 219% premium over the closing price of $4.39 on July 9, 2025 [3]. - The acquisition has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third or early fourth quarter of 2025 [3][4]. Strategic Implications - Upon completion, The Dallas Morning News will join Hearst Newspapers, which publishes 28 dailies and 50 weeklies across the U.S. [4]. - Hearst plans to invest in The Dallas Morning News' digital strategy and journalism, aiming to expand its audience reach [5]. - The acquisition aligns with Hearst's strategy of supporting trusted local media brands in growth markets [5]. Leadership Statements - Hearst Newspapers' president emphasized the commitment to support The Dallas Morning News through investments in digital strategy and journalism [5]. - The CEO of DallasNews highlighted the shared values with Hearst and the importance of their resources for the future of The Dallas Morning News [5]. Transition to Private Company - Following the acquisition, DallasNews Corporation will become a private entity, and its shares will no longer be traded on Nasdaq [5].

Core Viewpoint - CARGO Therapeutics has entered into a definitive merger agreement with Concentra Biosciences, where Concentra will acquire CARGO for $4.379 per share in cash, along with contingent value rights [1][2] Group 1: Merger Agreement Details - The acquisition price includes $4.379 in cash per share of CARGO common stock and one non-transferable contingent value right (CVR) [1] - The CVR entitles holders to receive 100% of CARGO's net cash exceeding $217.5 million and 80% of net proceeds from certain product candidates sold within two years post-closing [1] - The CARGO board unanimously approved the merger, deeming it in the best interests of all stockholders [2] Group 2: Tender Offer Process - Concentra will initiate a tender offer by July 21, 2025, to acquire all outstanding shares of CARGO common stock [3] - The closing of the offer is contingent upon the tender of a majority of outstanding shares and the availability of at least $217.5 million in cash at closing [3] - Approximately 17.4% of CARGO common stockholders have signed agreements to support the merger and tender their shares [3] Group 3: Advisors - TD Cowen is serving as the exclusive financial advisor to CARGO, while Latham & Watkins LLP is providing legal counsel to CARGO [4] - Gibson, Dunn & Crutcher LLP is acting as legal counsel to Concentra [4] Group 4: Company Background - CARGO Therapeutics is a biotechnology company focused on developing CAR T-cell therapies for cancer patients [5]

Core Viewpoint - Kaskela Law LLC has initiated an investigation into the fairness of the proposed buyout of NV5 Global, Inc. to assess whether the buyout price adequately reflects the company's value [1][3]. Group 1: Buyout Details - NV5 announced an agreement to be acquired by Acuren Corporation at a price of $23.00 per share, which includes $10.00 in cash and $13.00 in Acuren's stock [2]. - Following the transaction's completion, NV5's shareholders will be cashed out, and the company's shares will cease to be publicly traded [2]. Group 2: Investigation Focus - The investigation aims to determine if NV5's investors are receiving sufficient financial consideration for their shares and whether the company's officers or directors violated fiduciary duties or securities laws in agreeing to the buyout price [3]. - At the time of the announcement, at least one stock analyst had a price target of $28.00 per share for NV5, indicating a potential undervaluation in the proposed buyout [3].

Brazil’s presidential election in 2026 will be key to unlocking more action in the merger-and-acquisition market, some of the nation’s top investment bankers say https://t.co/fTn7IZoyEc ...